Dino Dujmovic
Zagreb, 10000, Croatia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP).
Journal: Medicina (Kaunas, Lithuania)
Published: January 20, 2024
Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins's Lymphoma Patients-A Single Centre Experience.
Journal: Cancers
Published: October 12, 2023
Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
Journal: European journal of haematology
Published: December 10, 2022
Efficacy and toxicity of infradiaphragmal radiotherapy fields in lymphoma patients: a single-centre experience.
Journal: La Radiologia medica
Published: November 09, 2022
The Impact of Achieving Complete Remission Prior to Allogeneic Stem Cell Transplantation on Progression-Free Survival in Hodgkin Lymphoma.
Journal: Clinical hematology international
Published: April 12, 2021
R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience.
Journal: Annals of hematology
Published: June 25, 2020
High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.
Journal: Annals of hematology
Published: November 30, 2015
Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma/leukemia.
Journal: Acta haematologica
Published: October 10, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026